サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793980

HIV関連脂肪異栄養症の世界市場

HIV-Associated Lipodystrophy

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
HIV関連脂肪異栄養症の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

HIV関連脂肪異栄養症の世界市場は2030年までに2億530万米ドルに達する見込み

2024年に1億8,030万米ドルと推定されるHIV関連脂肪異栄養症の世界市場は、分析期間2024-2030年にCAGR 2.2%で成長し、2030年には2億530万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口投与は、CAGR 1.6%を記録し、分析期間終了時には1億1,920万米ドルに達すると予測されます。注射剤投与セグメントの成長率は、分析期間でCAGR 3.2％と推定されます。

米国市場は4,910万米ドルと推定、中国はCAGR 4.2％で成長予測

米国のHIV関連脂肪異栄養症市場は、2024年に4,910万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.2%として、2030年までに3,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と1.6％と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界のHIV関連脂肪異栄養症市場- 主要動向と促進要因まとめ

抗レトロウイルス療法の進歩に伴い、HIV関連脂肪異栄養症の臨床的理解はどのように進展しているか？

HIV関連脂肪異栄養症は、特に旧世代の抗レトロウイルス薬による長期抗レトロウイルス療法を受けている人に生じる代謝的および美容的合併症として、ますます注目を集めています。この病態は、顔、四肢、臀部からの脂肪減少、あるいは腹部、頚部、乳房への脂肪蓄積を含む体脂肪の異常分布を特徴とします。抗レトロウイルス療法はHIV感染者の生存率と生活の質を劇的に改善したが、リポジストロフィーは依然として身体的、心理的、社会的な影響をもたらす根強い副作用です。HIV研究の進歩により、ミトコンドリア機能障害、サイトカイン不均衡、脂肪細胞代謝の変化など、リポジストロフィーの基礎となるメカニズムがより精緻に理解されるようになりました。現在、臨床医はリスクのある患者を特定することができるようになり、日常的なHIV管理にリポジストロフィーのスクリーニングを取り入れるようになっています。この病態が単なる美容上の問題にとどまらないという認識が、脂肪の再分布パターンや、インスリン抵抗性、脂質異常症、心血管リスクなどの関連代謝障害をモニターする努力を後押ししています。治療戦略は、患者のプロファイル、薬物歴、症状の程度に基づいて個別化されるようになってきています。安全性プロファイルが改善された新しい抗レトロウイルス薬は、重度の脂肪再分布の発生率を減少させるのに役立っているが、すでに罹患している患者にとっては依然として大きな課題です。臨床プロトコールが進化し続ける中で、健康と幸福に対するリポジストロフィーの長期的な影響を軽減するために、早期発見、継続的なモニタリング、脂質管理戦略の統合が優先されています。

HIV関連脂肪異栄養症の複雑な症状に対処するために、どのような治療法が出現しているか？

HIV関連脂肪異栄養症の管理は、薬理学的、外科的、ライフスタイルに基づいた介入を組み合わせて、身体的症状と基礎にある代謝の不均衡の両方に対処する多面的な試みとなっています。薬理学的戦略は、リポジストロフィーを悪化させることが知られている古い抗レトロウイルス薬から、代謝の副作用がより少ない新しい抗レトロウイルス薬への切り替えを含むように改良されています。現在では、インテグラーゼ阻害薬や第二世代プロテアーゼ阻害薬などの薬剤が、脂肪再分布のリスクを減らしながらウイルスを抑制できるため、好んで使用されています。脂肪萎縮症では、ポリ乳酸やヒアルロン酸を含む皮膚充填剤が、顔のボリュームを回復し、自己イメージに関する心理的転帰を改善するために使用されています。脂肪が蓄積している患者に対しては、成長ホルモン放出因子アナログであるテサモレリンなどのアプローチが内臓脂肪組織の減少に有効であることが示されています。また、体重管理と体組成の改善を目的として、栄養計画や運動療法などの生活習慣への介入も行われています。脂肪吸引術や脂肪移植術のような外科的治療も、より重症の症例には可能であるが、一般的には保存的治療に反応しない患者に限られています。さらに、脂肪細胞の分化と炎症を標的とする新たな治療法が臨床試験で検討されており、将来的には長期的な解決策を提供する可能性があります。この疾患の多面的な性質は、包括的なケアを提供するために、内分泌専門医、感染症専門医、形成外科専門医、精神保健専門医を含む協力的なアプローチを必要とします。このような集学的な対応は、患者が自分の体をコントロールする感覚を取り戻し、治療のアドヒアランスを維持する上で非常に重要です。

脂肪異栄養症の心理社会的影響は、患者中心のHIVケアモデルをどのように形成しているか？

HIV関連脂肪異栄養症の心理社会的負担は、HIVとともに生きる人々の間で、治療アドヒアランス、メンタルヘルス、QOLに影響を与える中心的な要因として認識されつつあります。主に体内で起こる他のHIV関連合併症とは異なり、脂肪異栄養症は目に見える形で現れ、しばしばスティグマ、羞恥心、社会的引きこもりにつながります。外見の変化、特に顔の衰えや中心部の脂肪蓄積は、常に病気を思い出させるものとなり、患者の自尊心や社会的自信を損なう。このような精神的な負担は、特にHIVに大きな汚名を着せられている地域では、社会的な誤解や情報公開への恐れによってさらに大きくなります。その結果、多くの患者が不安、抑うつ、身体イメージの問題と闘い、服薬コンプライアンスや全体的な健康転帰に悪影響を及ぼしかねないです。これに対し、ヘルスケア提供者は、HIVケアの心理的・社会的側面をより重視しています。カウンセリングサービス、ピアサポートネットワーク、教育ワークショップが治療プログラムに組み込まれ、患者に対話と対処戦略のための安全な空間を提供しています。遠隔医療プラットフォームもまた、継続的な関わりを促進し、臨床医が身体的・精神的健康の両方をモニターできるようになっています。患者支援団体やコミュニティ組織の台頭は、脂肪異栄養症の生活体験に関する認識を高め、再建治療への幅広いアクセスと包括的なケア政策を後押ししています。医療制度がHIV感染者の全人的なニーズに対応するようになるにつれて、脂肪異栄養症の心理社会的側面への対処は、もはや後回しにされるものではなく、効果的で思いやりのあるHIV管理の中核をなす要素となっています。

HIV関連脂肪異栄養症治療市場の成長を牽引する主な要因とは？

HIV関連脂肪異栄養症治療市場の成長は、世界的にHIVケアの形を変えつつある医療、技術、人口統計、社会的要因の組み合わせによってもたらされます。主な要因の一つは、長期HIV生存者の人口増加であり、その多くは脂肪異栄養症の素因となる古い抗レトロウイルスレジメンにさらされています。このような人々が高齢化するにつれ、脂肪の再分布とそれに伴う代謝合併症の長期的な影響により、専門的な治療に対する需要が高まっています。医薬品開発の進歩も大きな役割を果たしており、製薬会社はより安全な抗レトロウイルス療法や、脂肪蓄積を直接標的とするテサモレリンのような補助薬を発表しています。リポジストロフィーの重要性に対するヘルスケア専門家の意識の高まりは、早期診断と積極的な介入につながっており、これが市場の成長を支えています。国際的な資金援助と公衆衛生イニシアティブに支えられた新興市場における医療アクセスの拡大は、以前は報告されていなかったHIV関連疾患の診断と治療をさらに可能にしています。かつては任意治療や贅沢な治療とみなされていた美容・再建治療も、医療上必要な治療とみなされるようになってきており、それによって一部の地域では保険業者からの払い戻しを受けられるようになってきています。さらに、患者擁護や教育キャンペーンが治療を受けることを促し、スティグマを減らして市場への浸透を高めています。内分泌学、感染症の専門家、皮膚科、メンタルヘルスを組み合わせた集学的治療モデルの統合は、治療アプローチの有効性を高め、患者の転帰と長期的なアドヒアランスの向上を促進しています。これらの要因が相まって、臨床的有効性と患者の尊厳を両輪とするHIV関連脂肪異栄養症を管理するための、より迅速で進化したマーケットプレースが育まれています。

セグメント

投与経路（経口投与、注射投与、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc（formerly GlaxoSmithKline）
  • Janssen Global Services, LLC（A Johnson & Johnson Company）
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche（F. Hoffmann-La Roche Ltd.）
  • Sanofi S.A.
  • Theratechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited（a joint venture of GSK, Pfizer, and Shionogi）

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37101

Global HIV-Associated Lipodystrophy Market to Reach US$205.3 Million by 2030

The global market for HIV-Associated Lipodystrophy estimated at US$180.3 Million in the year 2024, is expected to reach US$205.3 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$119.2 Million by the end of the analysis period. Growth in the Injectable Administration segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$49.1 Million While China is Forecast to Grow at 4.2% CAGR

The HIV-Associated Lipodystrophy market in the U.S. is estimated at US$49.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$38.7 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global HIV-Associated Lipodystrophy Market - Key Trends & Drivers Summarized

How Is the Clinical Understanding of HIV-Associated Lipodystrophy Evolving with Advancements in Antiretroviral Therapy?

HIV-associated lipodystrophy is increasingly gaining attention as both a metabolic and cosmetic complication that arises in individuals undergoing long-term antiretroviral therapy, particularly with older generation drugs. This condition is characterized by abnormal distribution of body fat, including fat loss from the face, limbs, and buttocks, or fat accumulation in the abdomen, neck, and breasts. While antiretroviral therapy has drastically improved survival rates and quality of life for people living with HIV, lipodystrophy remains a persistent side effect that carries physical, psychological, and social implications. Advances in HIV research have led to a more refined understanding of the underlying mechanisms of lipodystrophy, which include mitochondrial dysfunction, cytokine imbalances, and alterations in adipocyte metabolism. Clinicians are now better able to identify patients at risk and are incorporating lipodystrophy screening into routine HIV management. The recognition of this condition as more than just a cosmetic issue has driven efforts to monitor fat redistribution patterns and associated metabolic disturbances such as insulin resistance, dyslipidemia, and cardiovascular risk. Treatment strategies are increasingly being individualized based on patient profiles, drug history, and extent of symptoms. Newer antiretroviral drugs with improved safety profiles are helping reduce the incidence of severe fat redistribution, though the challenge remains substantial for those already affected. As clinical protocols continue to evolve, early detection, ongoing monitoring, and integration of lipid management strategies are being prioritized to mitigate the long-term impact of lipodystrophy on health and well-being.

What Treatment Modalities Are Emerging to Address the Complex Symptoms of HIV-Associated Lipodystrophy?

The management of HIV-associated lipodystrophy has become a multifaceted endeavor, combining pharmacological, surgical, and lifestyle-based interventions to address both the physical symptoms and the underlying metabolic imbalances. Pharmacological strategies are being refined to include switching from older antiretroviral agents known to exacerbate lipodystrophy to newer classes with fewer metabolic side effects. Agents such as integrase inhibitors and second-generation protease inhibitors are now preferred, as they offer viral suppression with a reduced risk of fat redistribution. In cases of lipoatrophy, dermal fillers including polylactic acid and hyaluronic acid are being employed to restore facial volume and improve psychological outcomes related to self-image. For patients experiencing fat accumulation, approaches such as tesamorelin, a growth hormone-releasing factor analog, have demonstrated effectiveness in reducing visceral adipose tissue. Lifestyle interventions involving targeted nutrition plans and exercise regimens are also being prescribed to manage weight and improve body composition. Surgical options like liposuction or fat grafting remain available for more severe cases, though they are generally reserved for patients who do not respond to conservative treatments. Additionally, emerging therapies targeting adipocyte differentiation and inflammation are under investigation in clinical trials, potentially offering long-term solutions in the future. The multidimensional nature of the condition requires a collaborative approach involving endocrinologists, infectious disease specialists, plastic surgeons, and mental health professionals to provide comprehensive care. This multidisciplinary response is critical in helping patients regain a sense of control over their bodies and maintain treatment adherence.

How Is the Psychosocial Impact of Lipodystrophy Shaping Patient-Centered HIV Care Models?

The psychosocial burden of HIV-associated lipodystrophy is increasingly recognized as a central factor influencing treatment adherence, mental health, and quality of life among people living with HIV. Unlike other HIV-related complications that are primarily internal, lipodystrophy manifests visibly, often leading to stigma, embarrassment, and social withdrawal. Changes in physical appearance, especially facial wasting or central fat accumulation, can become constant reminders of the disease, undermining a patient’s self-esteem and social confidence. This emotional toll is compounded by societal misconceptions and the fear of disclosure, especially in regions where HIV remains heavily stigmatized. As a result, many patients struggle with anxiety, depression, and body image issues, which can negatively affect medication compliance and overall health outcomes. In response, healthcare providers are placing greater emphasis on the psychological and social dimensions of HIV care. Counseling services, peer support networks, and educational workshops are being integrated into treatment programs to offer patients a safe space for dialogue and coping strategies. Telehealth platforms are also facilitating continuous engagement, allowing clinicians to monitor both physical and emotional well-being. The rise of patient advocacy groups and community organizations is amplifying awareness about the lived experience of lipodystrophy, pushing for broader access to reconstructive treatments and inclusive care policies. As health systems become more attuned to the holistic needs of people with HIV, addressing the psychosocial aspects of lipodystrophy is no longer an afterthought but a core component of effective, compassionate HIV management.

What Key Factors Are Driving the Growth of the HIV-Associated Lipodystrophy Treatment Market?

The growth in the HIV-associated lipodystrophy treatment market is driven by a combination of medical, technological, demographic, and social factors that are reshaping HIV care globally. One of the primary drivers is the growing population of long-term HIV survivors, many of whom were exposed to older antiretroviral regimens that predisposed them to lipodystrophy. As these individuals age, the long-term effects of fat redistribution and associated metabolic complications are prompting increased demand for specialized treatments. Advances in drug development are also playing a major role, with pharmaceutical companies introducing safer antiretroviral therapies and adjunctive medications like tesamorelin that directly target fat accumulation. Rising awareness among healthcare professionals about the significance of lipodystrophy is leading to earlier diagnosis and proactive intervention, which is supporting market growth. The expansion of healthcare access in emerging markets, aided by international funding and public health initiatives, is further enabling diagnosis and treatment of HIV-related conditions that were previously underreported. Cosmetic and reconstructive treatments, once considered optional or luxury interventions, are being increasingly viewed as medically necessary, thereby attracting reimbursement from insurance providers in some regions. Additionally, patient advocacy and education campaigns are encouraging individuals to seek treatment, reducing stigma and improving market penetration. The integration of multidisciplinary care models that combine endocrinology, infectious disease expertise, dermatology, and mental health is enhancing the effectiveness of treatment approaches, driving better patient outcomes and long-term adherence. Together, these drivers are fostering a more responsive and evolving marketplace for managing HIV-associated lipodystrophy with both clinical efficacy and patient dignity at its center.

SCOPE OF STUDY:

The report analyzes the HIV-Associated Lipodystrophy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Administration, Injectable Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc (formerly GlaxoSmithKline)
  • Janssen Global Services, LLC (A Johnson & Johnson Company)
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Sanofi S.A.
  • Theratechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited (a joint venture of GSK, Pfizer, and Shionogi)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HIV-Associated Lipodystrophy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing HIV Patient Population Under Long-Term ART Therapy Throws the Spotlight on Lipodystrophy as a Chronic Complication
    • Increased Awareness Among Clinicians and Patients Propels Early Diagnosis and Targeted Intervention
    • Rising Demand for Body Fat Redistribution Therapies Strengthens Business Case for Specialized Treatments
    • Advancements in Antiretroviral Drug Formulations Drive Reduction in Lipodystrophy Risk but Sustain Market for Legacy Patients
    • Expansion of Aesthetic and Reconstructive Treatment Options Spurs Interest in Cosmetic Management of Facial Lipoatrophy
    • Novel Therapies Accelerate Access to Lipodystrophy-Specific Medications
    • Psychosocial Impact of Disfigurement Generates Demand for Holistic and Mental Health-Integrated Treatment Plans
    • R&D in Adipogenesis and Metabolic Pathway Modulation Throws the Spotlight on Innovative Therapeutic Mechanisms
    • Growing Use of Injectable Poly-L-Lactic Acid and Dermal Fillers Expands Non-Surgical Treatment Options
    • Increased Insurance Coverage and Reimbursement Support Drives Market Accessibility for Approved Treatments
    • Limited Availability of Biomarkers and Diagnostic Tools Poses Challenges to Personalized Lipodystrophy Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV-Associated Lipodystrophy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV-Associated Lipodystrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HIV-Associated Lipodystrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION